. . "cardiovascular risk; combined treatment; ezetimib; fibrates; statins and diabetes; statins; Diabetic dyslipidemia"@en . "CZ - \u010Cesk\u00E1 republika" . . "11110" . "16" . . . . "V" . "RIV/00216208:11110/14:10293213" . . "\u010Ce\u0161ka, Richard" . . "Lipids and diabetes: selected questions (and answers?)"@en . . "Lipidy a diabetes: vybran\u00E9 ot\u00E1zky (a odpov\u011Bdi?)" . "1"^^ . "4" . . . "Postgradu\u00E1ln\u00ED medic\u00EDna" . . "Lipidy a diabetes: vybran\u00E9 ot\u00E1zky (a odpov\u011Bdi?)"@cs . "Lipidy a diabetes: vybran\u00E9 ot\u00E1zky (a odpov\u011Bdi?)" . "1"^^ . . "26313" . . . "5"^^ . "V posledn\u00EDch letech je \u010Dasto zd\u016Fraz\u0148ov\u00E1n v\u00FDznam diabetu 2. typu jako nejv\u00FDznamn\u011Bj\u0161\u00EDho rizikov\u00E9ho faktoru pro kardiovaskul\u00E1rn\u00ED onemocn\u011Bn\u00ED. Zd\u00E1 se ov\u0161em, \u017Ee diabetes 2. typu p\u0159edstavuje v\u00FDznamn\u00E9 riziko zejm\u00E9na v situaci, kdy je prov\u00E1zen clusterem dal\u0161\u00EDch rizikov\u00FDch faktor\u016F, zejm\u00E9na hyperlipoprotein\u00E9mi\u00ED/dyslipid\u00E9mi\u00ED. Realita l\u00E9\u010Dby dyslipid\u00E9mi\u00ED u diabetik\u016F m\u00E1 ale v ka\u017Edodenn\u00ED praxi st\u00E1le velk\u00E9 rezervy. P\u0159itom pro hypolipidemika (p\u0159edev\u0161\u00EDm statiny, ale i pro fibr\u00E1ty, a dokonce i ezetimib) existuje \u0159ada p\u0159esv\u011Bd\u010Div\u00FDch d\u016Fkaz\u016F z hlediska jejich vlivu na sn\u00ED\u017Een\u00ED rizika kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED." . "RIV/00216208:11110/14:10293213!RIV15-MSM-11110___" . "Lipidy a diabetes: vybran\u00E9 ot\u00E1zky (a odpov\u011Bdi?)"@cs . "http://zdravi.e15.cz/clanek/postgradualni-medicina/lipidy-a-diabetes-vybrane-otazky-a-odpovedi-474963" . . "In recent years, the significance of type 2 diabetes as the most important risk factor for cardiovascular diseases is often emphasised. It seems however that type 2 diabetes represents a significant risk especially in situations where it is accompanied by a cluster of other risk factors, especially hyperlipoproteinemia/ dyslipidemia. In practice, there is much to improve about the treatment of dyslipidemias in patients with diabetes, even though there exists convincing evidence that hypolipidemics (especially statins, but fibrates as well and even ezetimib) have a beneficial influence on reducing the risk of cardiovascular diseases."@en . "V posledn\u00EDch letech je \u010Dasto zd\u016Fraz\u0148ov\u00E1n v\u00FDznam diabetu 2. typu jako nejv\u00FDznamn\u011Bj\u0161\u00EDho rizikov\u00E9ho faktoru pro kardiovaskul\u00E1rn\u00ED onemocn\u011Bn\u00ED. Zd\u00E1 se ov\u0161em, \u017Ee diabetes 2. typu p\u0159edstavuje v\u00FDznamn\u00E9 riziko zejm\u00E9na v situaci, kdy je prov\u00E1zen clusterem dal\u0161\u00EDch rizikov\u00FDch faktor\u016F, zejm\u00E9na hyperlipoprotein\u00E9mi\u00ED/dyslipid\u00E9mi\u00ED. Realita l\u00E9\u010Dby dyslipid\u00E9mi\u00ED u diabetik\u016F m\u00E1 ale v ka\u017Edodenn\u00ED praxi st\u00E1le velk\u00E9 rezervy. P\u0159itom pro hypolipidemika (p\u0159edev\u0161\u00EDm statiny, ale i pro fibr\u00E1ty, a dokonce i ezetimib) existuje \u0159ada p\u0159esv\u011Bd\u010Div\u00FDch d\u016Fkaz\u016F z hlediska jejich vlivu na sn\u00ED\u017Een\u00ED rizika kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED."@cs . "1212-4184" . . "Lipids and diabetes: selected questions (and answers?)"@en . "[E7C38274FC0F]" . .